US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.
You may also be interested in...
ORA represented only a small fraction of the user fee programs’ costs in recent years, but wants to show its importance to the review process.
Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.
Additional hiring in FDA’s FY 2022 budget request also is expected to help address the inspections delayed by the coronavirus pandemic.